Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers

American Journal of Psychiatry

Volumn 154, Issue 6, 1997, Pages 805-811

  Breier, Alan ^a   Malhotra, Anil K ^a   Pinals, Debra A ^a   Weisenfeld, Neil I ^a   Pickar, David ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; KETAMINE;

ADULT; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

EID: 0030966452     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.6.805     Document Type: Article

References (45)

1. 3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 1979; 76:5372-5376
2. Vincent JP, Kartalovski B, Geneste P, Kamenka JM, Lazdunski M: Interaction of phencyclidine ("angel dust") with a specific receptor in rat brain membranes. Proc Natl Acad Sci USA 1979; 76:4678-4682
3. Corssen G, Domino EF: Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 1966; 45:29-40
4. Meyer JS, Greifenstein F, DeVault M: A new drug causing symptoms of sensory deprivation. J Nerv Ment Dis 1959; 129:54-61
5. Bakker CB, Amini FB: Observations on the psychotomimetic effects of Sernyl. Compr Psychiatry 1961; 2:269-280
6. Luby ED, Cohen BD, Rosenbaum F, Gottlieb J, Kelley R: Study of a new schizophrenomimetic drug, Sernyl. Arch Neurol Psychiatry 1959; 81:363-369
7. Ban TA, Lohrenz JJ, Lehmann HE: Observations on the action of Sernyl - a new psychotropic drug. Can Psychiatr Assoc J 1961; 6:150-156
8. Davis BM, Beech HR: The effect of 1-arylcyclohexylamine (Sernyl) on twelve normal volunteers. J Ment Sci 1960; 106:912-924
9. Olney JW, Labruyere J, Price MT: Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989; 244:1360-1362
10. White PF, Way WL, Trevor AJ: Ketamine - its pharmacology and therapeutic uses. Anesthesiology 1982; 56:119-136
11. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A: NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996; 14:301-307
12. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51:199-214
13. Monaghan DT, Buller AL: Anatomical, pharmacological, and molecular diversity of native NMDA receptor subtypes, in The NMDA Receptor, 2nd ed. Edited by Collingridge GL, Watkins JC. New York, Oxford University Press, 1995, pp 158-176
14. Crosby G, Crane AM, Sokoloff L: Local changes in cerebral glucose utilization during ketamine anesthesia. Anesthesiologist 1982; 56:437-443
15. Tamminga CA, Tanimoto K, Kuo S, Chase TN, Contreras PC, Rice KC, Jackson AE, O'Donohue TL: PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCP-receptor-acylating agent. Synapse 1987; 1:497-504
16. Meibach RC, Glick SD, Cox R, Maayani S: Localisation of phencyclidine-induced changes in brain energy metabolism. Nature 1979; 282:625-626
17. Hammer RP, Herkenham M: Altered metabolic activity in the cerebral cortex of rats exposed to ketamine. J Comp Neurol 1983; 220:396-404
18. Gao XM, Shirakawa O, Du F, Tamminga CA: Delayed regional metabolic actions of phencyclidine. Eur J Pharmacol 1993; 241: 7-15
19. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA: Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995; 6:869-872
20. Spitzer RL, Williams JBW, Gibbon M, First MB: Instruction Manual for the Structured Clinical Interview for DSM-III-R (SCID). New York, New York State Psychiatric Institute, Biometrics Research, 1989
21. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthesized albino rat. J Neurochem 1977; 28:897-916
22. Talairach J, Tournoux P: Co-Planar Stereotaxic Atlas of the Human Brain. New York, Thieme Medical, 1988
23. Woods RP, Cherry SR, Mazziotta JC: Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 1992; 16:620-633
24. Friston KJ, Frith CD, Liddle PF, Lammertsma AA, Dolan RD, Frackowiak RSJ: The relationship between local and global changes in PET scans. J Cereb Blood Flow Metab 1990; 10:458-466
25. Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ: Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 1991; 11:690-699
26. Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ: Plastic transformation of PET images. J Comput Assist Tomogr 1991; 15: 634-639
27. Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC: Assessing the significance of focal activations using their spatial extent. Human Brain Mapping 1994; 1:210-220
28. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
29. 3H phencyclidine in brain membranes. Life Sci 1982; 30:2147-2154
30. Oye I, Paulsen O, Maruset A: Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992; 260:1209-1213
31. Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148:1301-1308
32. Byrd LD, Standish LJ, Howell LL: Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs. Eur J Pharmacol 1987; 144:331-341
33. Weissman AD, Dam M, London ED: Alterations in local glucose utilization induced by phencyclidine. Brain Res 1987; 435:29-40
34. Fuster JM: The Prefrontal Cortex, 2nd ed. New York, Raven Press, 1989
35. Cotman CW, Monaghan DT: Chemistry and anatomy of excitatory amino acid systems, in Psychopharmacology: The Third Generation of Progress. Edited by Meltzer HY. New York, Raven Press, 1987, pp 197-210
36. Goldman PS, Rosvold HE, Vest B, Galkin TW: Analysis of the delayed-alternation deficit produced by dorsolateral prefrontal lesions in the rhesus monkey. J Comp Physiol Psychol 1971; 77: 212-220
37. Mishkin M, Manning FJ: Nonspatial memory after selective prefrontal lesions in monkeys. Brain Res 1978; 143:313-323
38. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RSJ: Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 1992; 160:179-186
39. McGuire PK, Shah GM, Murray RM: Increased blood flow in Broca's area during auditory hallucinations in schizophrenia. Lancet 1993; 342:703-706
40. Andreasen NC, Rezai K, Alliger R, Swayze VW II, Flaum M, Kirchner P, Cohen G, O'Leary DS: Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch Gen Psychiatry 1992; 49:943-958
41. Weinberger DR, Berman KF: Speculation on the meaning of cerebral metabolic hypofrontality in schizophrenia. Schizophr Bull 1988; 14:157-168
42. Buchsbaum MS, Haier RJ, Potkin SG, Nuechterlein K, Bracha HS, Katz M, Lohr J, Wu J, Lottenberg S, Jerabek PA, Trenary M, Tafalla R, Reynolds C, Bunney WE Jr: Frontostriatal disorder of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry 1992; 49:935-942
43. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, Swaward J, McKenna P, Chua SE, Schnorr L: A functional neuroanatomy of hallucinations in schizophrenia. Nature 1995; 378:176-179
44. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J: Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992; 49:959-965
45. Andreasen NC: Neural mechanisms of negative symptoms. Br J Psychiatry Suppl 1989; 7:93-98